Warfarin Pharmacogenomics in Diverse Populations

Justin B. Kaye, Lauren E. Schultz, Heidi E. Steiner, Rick A Kittles, Larisa H. Cavallari, Jason H. Karnes

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Genotype-guided warfarin dosing algorithms are a rational approach to optimize warfarin dosing and potentially reduce adverse drug events. Diverse populations, such as African Americans and Latinos, have greater variability in warfarin dose requirements and are at greater risk for experiencing warfarin-related adverse events compared with individuals of European ancestry. Although these data suggest that patients of diverse populations may benefit from improved warfarin dose estimation, the vast majority of literature on genotype-guided warfarin dosing, including data from prospective randomized trials, is in populations of European ancestry. Despite differing frequencies of variants by race/ethnicity, most evidence in diverse populations evaluates variants that are most common in populations of European ancestry. Algorithms that do not include variants important across race/ethnic groups are unlikely to benefit diverse populations. In some race/ethnic groups, development of race-specific or admixture-based algorithms may facilitate improved genotype-guided warfarin dosing algorithms above and beyond that seen in individuals of European ancestry. These observations should be considered in the interpretation of literature evaluating the clinical utility of genotype-guided warfarin dosing. Careful consideration of race/ethnicity and additional evidence focused on improving warfarin dosing algorithms across race/ethnic groups will be necessary for successful clinical implementation of warfarin pharmacogenomics. The evidence for warfarin pharmacogenomics has a broad significance for pharmacogenomic testing, emphasizing the consideration of race/ethnicity in discovery of gene–drug pairs and development of clinical recommendations for pharmacogenetic testing.

Original languageEnglish (US)
Pages (from-to)1150-1163
Number of pages14
JournalPharmacotherapy
Volume37
Issue number9
DOIs
StatePublished - Sep 1 2017

Fingerprint

Pharmacogenetics
Warfarin
Population
Genotype
Ethnic Groups
Drug-Related Side Effects and Adverse Reactions
Hispanic Americans
African Americans

Keywords

  • anticoagulation
  • diversity
  • pharmacogenomics
  • warfarin

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Kaye, J. B., Schultz, L. E., Steiner, H. E., Kittles, R. A., Cavallari, L. H., & Karnes, J. H. (2017). Warfarin Pharmacogenomics in Diverse Populations. Pharmacotherapy, 37(9), 1150-1163. https://doi.org/10.1002/phar.1982

Warfarin Pharmacogenomics in Diverse Populations. / Kaye, Justin B.; Schultz, Lauren E.; Steiner, Heidi E.; Kittles, Rick A; Cavallari, Larisa H.; Karnes, Jason H.

In: Pharmacotherapy, Vol. 37, No. 9, 01.09.2017, p. 1150-1163.

Research output: Contribution to journalReview article

Kaye, JB, Schultz, LE, Steiner, HE, Kittles, RA, Cavallari, LH & Karnes, JH 2017, 'Warfarin Pharmacogenomics in Diverse Populations', Pharmacotherapy, vol. 37, no. 9, pp. 1150-1163. https://doi.org/10.1002/phar.1982
Kaye JB, Schultz LE, Steiner HE, Kittles RA, Cavallari LH, Karnes JH. Warfarin Pharmacogenomics in Diverse Populations. Pharmacotherapy. 2017 Sep 1;37(9):1150-1163. https://doi.org/10.1002/phar.1982
Kaye, Justin B. ; Schultz, Lauren E. ; Steiner, Heidi E. ; Kittles, Rick A ; Cavallari, Larisa H. ; Karnes, Jason H. / Warfarin Pharmacogenomics in Diverse Populations. In: Pharmacotherapy. 2017 ; Vol. 37, No. 9. pp. 1150-1163.
@article{397f2f4cfa4a46f5bf77931cb3bb1931,
title = "Warfarin Pharmacogenomics in Diverse Populations",
abstract = "Genotype-guided warfarin dosing algorithms are a rational approach to optimize warfarin dosing and potentially reduce adverse drug events. Diverse populations, such as African Americans and Latinos, have greater variability in warfarin dose requirements and are at greater risk for experiencing warfarin-related adverse events compared with individuals of European ancestry. Although these data suggest that patients of diverse populations may benefit from improved warfarin dose estimation, the vast majority of literature on genotype-guided warfarin dosing, including data from prospective randomized trials, is in populations of European ancestry. Despite differing frequencies of variants by race/ethnicity, most evidence in diverse populations evaluates variants that are most common in populations of European ancestry. Algorithms that do not include variants important across race/ethnic groups are unlikely to benefit diverse populations. In some race/ethnic groups, development of race-specific or admixture-based algorithms may facilitate improved genotype-guided warfarin dosing algorithms above and beyond that seen in individuals of European ancestry. These observations should be considered in the interpretation of literature evaluating the clinical utility of genotype-guided warfarin dosing. Careful consideration of race/ethnicity and additional evidence focused on improving warfarin dosing algorithms across race/ethnic groups will be necessary for successful clinical implementation of warfarin pharmacogenomics. The evidence for warfarin pharmacogenomics has a broad significance for pharmacogenomic testing, emphasizing the consideration of race/ethnicity in discovery of gene–drug pairs and development of clinical recommendations for pharmacogenetic testing.",
keywords = "anticoagulation, diversity, pharmacogenomics, warfarin",
author = "Kaye, {Justin B.} and Schultz, {Lauren E.} and Steiner, {Heidi E.} and Kittles, {Rick A} and Cavallari, {Larisa H.} and Karnes, {Jason H.}",
year = "2017",
month = "9",
day = "1",
doi = "10.1002/phar.1982",
language = "English (US)",
volume = "37",
pages = "1150--1163",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "9",

}

TY - JOUR

T1 - Warfarin Pharmacogenomics in Diverse Populations

AU - Kaye, Justin B.

AU - Schultz, Lauren E.

AU - Steiner, Heidi E.

AU - Kittles, Rick A

AU - Cavallari, Larisa H.

AU - Karnes, Jason H.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Genotype-guided warfarin dosing algorithms are a rational approach to optimize warfarin dosing and potentially reduce adverse drug events. Diverse populations, such as African Americans and Latinos, have greater variability in warfarin dose requirements and are at greater risk for experiencing warfarin-related adverse events compared with individuals of European ancestry. Although these data suggest that patients of diverse populations may benefit from improved warfarin dose estimation, the vast majority of literature on genotype-guided warfarin dosing, including data from prospective randomized trials, is in populations of European ancestry. Despite differing frequencies of variants by race/ethnicity, most evidence in diverse populations evaluates variants that are most common in populations of European ancestry. Algorithms that do not include variants important across race/ethnic groups are unlikely to benefit diverse populations. In some race/ethnic groups, development of race-specific or admixture-based algorithms may facilitate improved genotype-guided warfarin dosing algorithms above and beyond that seen in individuals of European ancestry. These observations should be considered in the interpretation of literature evaluating the clinical utility of genotype-guided warfarin dosing. Careful consideration of race/ethnicity and additional evidence focused on improving warfarin dosing algorithms across race/ethnic groups will be necessary for successful clinical implementation of warfarin pharmacogenomics. The evidence for warfarin pharmacogenomics has a broad significance for pharmacogenomic testing, emphasizing the consideration of race/ethnicity in discovery of gene–drug pairs and development of clinical recommendations for pharmacogenetic testing.

AB - Genotype-guided warfarin dosing algorithms are a rational approach to optimize warfarin dosing and potentially reduce adverse drug events. Diverse populations, such as African Americans and Latinos, have greater variability in warfarin dose requirements and are at greater risk for experiencing warfarin-related adverse events compared with individuals of European ancestry. Although these data suggest that patients of diverse populations may benefit from improved warfarin dose estimation, the vast majority of literature on genotype-guided warfarin dosing, including data from prospective randomized trials, is in populations of European ancestry. Despite differing frequencies of variants by race/ethnicity, most evidence in diverse populations evaluates variants that are most common in populations of European ancestry. Algorithms that do not include variants important across race/ethnic groups are unlikely to benefit diverse populations. In some race/ethnic groups, development of race-specific or admixture-based algorithms may facilitate improved genotype-guided warfarin dosing algorithms above and beyond that seen in individuals of European ancestry. These observations should be considered in the interpretation of literature evaluating the clinical utility of genotype-guided warfarin dosing. Careful consideration of race/ethnicity and additional evidence focused on improving warfarin dosing algorithms across race/ethnic groups will be necessary for successful clinical implementation of warfarin pharmacogenomics. The evidence for warfarin pharmacogenomics has a broad significance for pharmacogenomic testing, emphasizing the consideration of race/ethnicity in discovery of gene–drug pairs and development of clinical recommendations for pharmacogenetic testing.

KW - anticoagulation

KW - diversity

KW - pharmacogenomics

KW - warfarin

UR - http://www.scopus.com/inward/record.url?scp=85029440591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029440591&partnerID=8YFLogxK

U2 - 10.1002/phar.1982

DO - 10.1002/phar.1982

M3 - Review article

C2 - 28672100

AN - SCOPUS:85029440591

VL - 37

SP - 1150

EP - 1163

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 9

ER -